Latest Conference Articles

February 13th 2019, 11:56pm

Genitourinary Cancers Symposium (ASCO GU)

Nivolumab combined with low-dose ipilimumab continued to demonstrate strong responses and a survival benefit at 30 months’ follow-up as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.

February 12th 2019, 3:08am

Genitourinary Cancers Symposium (ASCO GU)

The combination of pembrolizumab (Keytruda) and axitinib (Inlyta) was associated with a significantly longer progression-free and overall survival compared with sunitinib (Sutent) in treatment-naïve patients with clear cell metastatic renal cell carcinoma.

February 12th 2019, 3:06am

Genitourinary Cancers Symposium (ASCO GU)

African-American men with metastatic castration-resistant prostate cancer treated with novel hormonal therapies—namely abiraterone acetate or enzalutamide—lived 20% longer than their Caucasian counterparts.

February 12th 2019, 3:00am

Genitourinary Cancers Symposium (ASCO GU)

The novel targeted radiation therapy lutetium-177 PSMA-617 showed strong clinical activity and the potential to improve survival in heavily pretreated men with PSMA-positive metastatic castration-resistant prostate cancer.

January 29th 2019, 3:36am

PER® Winter Lung Cancer Conference

Until more biomarkers are available, the use of tumor mutational burden with PD-L1 expression could help oncologists further personalize immunotherapy choices for patients with non–small cell lung cancer.

January 29th 2019, 12:12am

PER® Winter Lung Cancer Conference

Mark A. Socinski, MD, provides an overview of treatment advances in the lung cancer landscape, and highlights where much-needed work still remains.

January 28th 2019, 10:50pm

PER® Winter Lung Cancer Conference

Findings from the PACIFIC trial have made a significant impact on the treatment of patients with unresectable stage III non–small cell lung cancer, especially in light of the history of treatment options in this setting.

January 28th 2019, 8:45am

PER® Winter Lung Cancer Conference

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses the current role of radiation therapy in the treatment of patients with non–small cell lung cancer.

January 28th 2019, 5:21am

PER® Winter Lung Cancer Conference

Despite the rapidly expanding therapeutic options available in immunotherapy for patients with non-small cell lung cancer, there are still a number of drawbacks to treatment, explaining why not all patients respond to current treatment options.

January 28th 2019, 1:04am

PER® Winter Lung Cancer Conference

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the eligibility criteria for immunotherapy trials in non–small cell lung cancer.

January 28th 2019, 1:03am

PER® Winter Lung Cancer Conference

Data on many new treatment options have come forward over the past year highlighting the potential to treat more emerging oncogenic drivers impacting smaller subsets of patients with non–small cell lung cancer.

January 28th 2019, 12:14am

PER® Winter Lung Cancer Conference

Eric Vallieres, MD, highlights the technological advances of lung cancer surgery and how this impacts the outlook for patients who are candidates for it.

January 27th 2019, 11:44pm

PER® Winter Lung Cancer Conference

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses the current state of treatment in patients with non–small cell lung cancer.

January 27th 2019, 4:51am

PER® Winter Lung Cancer Conference

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses traditional and emerging treatment approaches for patients with mesothelioma.

January 27th 2019, 4:39am

PER® Winter Lung Cancer Conference

A growing focus on smaller oncogenic drivers in lung cancer has opened up new treatment options and many potential drugs in development for patients with less common alterations.

January 27th 2019, 12:45am

PER® Winter Lung Cancer Conference

The treatment paradigm for EGFR-mutant non–small cell lung cancer has grown significantly with many EGFR TKIs now available to treat patients with this disease.

January 27th 2019, 12:36am

PER® Winter Lung Cancer Conference

Rogerio Lilenbaum, MD, highlights the current treatment approaches for patients with EGFR-positive non–small cell lung cancer and shed light on the potential for immunotherapy in the space.

January 26th 2019, 10:20pm

PER® Winter Lung Cancer Conference

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing immune-related adverse events in lung cancer.

January 26th 2019, 9:38pm

PER® Winter Lung Cancer Conference

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the potential for immunotherapy in the treatment of patients with EGFR-positive non–small cell lung cancer.

January 22nd 2019, 1:21am

SGO Winter Meeting

Successful application of immunotherapy in endometrial cancer means identifying the patients with inflamed tumors who will respond to treatment and those who will not, and finding ways to treat noninflamed tumors with immunotherapy agents.